Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Scientists engineer self-destructing bacteria to kill cancer cells
Salmonella bacteria
Hasty and his team synchronised the bacteria to release bursts of known cancer drugs when a bacterial colony self-destructs within the tumour.
In vivo method minimises damage to surrounding cells

Scientists at the University of California and the Massachusetts Institute have discovered a therapeutic approach to cancer that minimises damage to surrounding cells.

A study published in the journal Nature describes how researchers engineered self-destructing bacteria that release anti-cancer drugs within tumours.

“In synthetic biology, one goal of therapeutics is to target disease sites and minimise damage,” said lead author Jeff Hasty, professor of bioengineering and biology at UC San Diego.

In the study, Hasty and his team synchronised the bacteria to release bursts of known cancer drugs when a bacterial colony self-destructs within the tumour.

Researchers say the use of bacteria to deliver cancer drugs in vivo is 'enticing' because conventional chemotherapy doesn't always reach the inner regions of a tumour.

Importantly, the researchers observed the combination of chemotherapy and the gene products produced by the bacterial circuit consistently reduced tumour size.

“The new work by Jeff Hasty and team is a brilliant demonstration of how theory in synthetic biology can lead to clinically meaningful advances,” said Jim Collins, a founder of the field of synthetic biology.

“Over a decade ago during the early days of the field, Jeff developed a theoretical framework for synchronising cellular processes across a community of cells. Now his team has shown experimentally how one can harness such effects to create a novel, clinically viable therapeutic approach.”

Become a member or log in to add this story to your CPD history

Equine Disease Surveillance report released for Q4 2025

News Story 1
 The latest Equine Disease Surveillance report has been released, with details on equine disease from Q4 of 2025.

The report, produced by Equine Infectious Disease Surveillance, includes advice on rule changes for equine influenza vaccination.

Statistics and maps detail recent outbreaks of equine herpes virus, equine influenza, equine strangles and equine grass sickness. A series of laboratory reports provides data on virology, bacteriology, parasitology and toxicosis.

This issue also features a case study of orthoflavivus-associated neurological disease in a horse in the UK. 

Click here for more...
News Shorts
RCVS annual renewal fee for vets due

RCVS' annual renewal fee for veterinary surgeons is now due. Vets must pay their renewal fee before Wednesday, 1 April 2026.

This year's standard annual fee has increased to 431 from last year's 418. This is an approximately three per cent increase, as approved by RCVS Council and the Privy Council.

Tshidi Gardner, RCVS treasurer, said: "The small fee increase will be used to help deliver both our everyday activities and our new ambitious Strategic Plan, which includes aims such as achieving new legislation, reviewing the Codes of Professional Conduct and supporting guidance, and continuing to support the professions through activities such as the Mind Matters Initiative, RCVS Academy and career development."

A full breakdown of the new fees is on the RCVS website. Information about tax relief is available on the UK government website.